Immune responses associated with mpox viral clearance in men with and without HIV in Spain: a multisite, observational, prospective cohort study
Igor Moraes-Cardoso, Susana Benet, Julieta Carabelli, Daniel Perez-Zsolt, Adrià Mendoza, Àngel Rivero, Andrea Alemany, Vicente Descalzo, Yovaninna Alarcón-Soto, Alba Grifoni, Alessandro Sette, José Moltó, Aurélien Marc, Michael Marks, Oriol Mitjà, Christian Brander, Roger Paredes, Nuria Izquierdo‐Useros, Jorge Carrillo, Clara Suñer, Àlex Olvera, Beatriz Mothe, Beatriz Mothe, Beatriz Mothe, Yovaninna Alarcón Soto, Andrea Alemany, Lucía Bailón, Susana Benet, Oriol Mitjà, Beatriz Mothe, Beatriz Mothe, Roger Paredes, Sofía Sabato, Clara Suñer, Clara Suñer, Pamela Torrano, Maria Ubals, Rytis Boreika, Christian Brander, Julieta Carabelli, Jorge Carrillo, Marçal Gallemí, Nuria Izquierdo-Useros, Elisa Molina-Molina, Igor Moraes-Cardoso, Jordana Muñoz-Basagoiti, Alex Olvera, Daniel Perez-Zsolt, Dàlia Raïch-Regué, Pep Coll, Javier Fernández, Adrià Mendoza, Félix Pérez, Joan Reguant, Angel Rivero, Maider Arando, Vicente Descalzo, Jorge Néstor Garcia, Arnau Monforte, Patricia Álvarez, Jeremie Guedj, Aurélien Marc, Michael Marks
Abstract
BACKGROUND: Since the emergence of the global mpox outbreak in May, 2022, more than 90 000 cases have been diagnosed across 110 countries, disproportionately affecting people with HIV. The durability of mpox-specific immunity is unclear and reinfections have been reported. We aimed to compare mpox immune responses up to 6 months after diagnosis in participants with and without HIV and assess their effect on disease severity and viral clearance dynamics. METHODS: This study was embedded within a prospective, observational, multicentre cohort study of viral clearance dynamics among people with mpox in Spain (MoViE). We included women and men aged 18 years or older, who had signs of mpox, and reported having symptom onset within the previous 10 days at the moment of mpox diagnosis from three sex clinics of the Barcelona metropolitan area. Samples from skin ulcers were collected weekly to estimate the time to clear monkeypox virus (MPXV) from skin lesions. Blood samples were taken at diagnosis, 29, 91, and 182 days later for immune analysis. This included quantifying IgG and IgA against three mpox antigens by ELISA, evaluating in-vitro neutralisation, and characterising mpox-specific T-cell responses using interferon γ detecting enzyme-linked immunospot (ELISpot) assay and multiparametric flow cytometry. FINDINGS: T-cell count median of 777 cells per μL (IQR 484-1533), and 11 (78%) of 14 were virally suppressed on antiretroviral therapy. Nine (27%) of 33 participants were age 49 years or older. 15 (45%) of 33 participants were originally from Spain, and all participants were men. Early humoral responses, particularly concentrations and breadth of IgG and IgA, were associated with milder disease and faster viral clearance. Orthopoxvirus-specific T cells count was also positively correlated with MPXV clearance. Antibody titres declined more rapidly in participants with HIV, but T-cell responses against MPXV were sustained up to day 182 after diagnosis, regardless of HIV status. INTERPRETATION: Higher breadth and magnitude of B-cell and T-cell responses are important in facilitating local viral clearance, limiting mpox dissemination, and reducing disease severity in individuals with preserved immune system. Antibodies appear to contribute to early viral control and T-cell responses are sustained over time, which might contribute to milder presentations during reinfection. FUNDING: Fundació Lluita contra les Infeccions, IrsiCaixa, and Consorcio Centro de Investigación Biomédica en Red, Instituto de Salud Carlos III, Ministerio de Ciencia, Innovación e Universidades.